胸痹方治疗冠状动脉粥样硬化性心脏病心力衰竭临床研究

Clinical Study of Xiongbi Prescription in Treatment Heart Failure with Coronary Atherosclerotic Heart Disease

目的:观察胸痹方对冠状动脉粥样硬化性心脏病(简称冠心病)心力衰竭的临床疗效。方法:选取冠心病合并心力衰竭患者60例,随机分为两组,对照组30例给予常规西药治疗;治疗组30例在常规西药治疗基础上口服胸痹方治疗,两组疗程均为8周。分析两组患者治疗前后中医证候积分、心电图、心功能、6分钟步行距离等指标的变化情况,评价临床疗效。结果:两组患者治疗后中医证候积分、心电图、心功能、6分钟步行距离均有改善,与对照组比较,差异均有统计学意义(P<0.05)。结论:胸痹方可明显改善冠心病心力衰竭患者心功能,提高生活质量,临床疗效显著。

Objective： To observe the clinical curative effect of Xiongbi Prescription in treatment of heart failure with Coronary atherosclerotic heart disease（ CHD） in patients. Methods： Sixty patients of heart failure with coronary atherosclerotic heart disease were randomly divided into two groups. The control group（ n = 30） received conventional western medicine. The treatment group（ n =30） received treatment of Xiongbi Prescription in addition to that of the conventional western medicine. The changes of TCM syndrome scores,electrocardiogram,cardiac function and 6-minute walking distances of both groups were analyzed before and after treatment,and the clinical curative effects were evaluated. Results： The TCM syndrome scores,electrocardiogram,cardiac function and 6-minute walking distances of the two groups were improved after treatment. Compared with those of the control group,the differences were statistically significant（ P〈0. 05）. Conclusion： Xiongbi Prescription can obviously improve the heart function of patients with heart failure with coronary atherosclerotic heart disease and improve the quality of life The clinical efficacy is remarkable.